{"type":"trials","record":{"id":41739,"source_id":"clinicaltrials-gov","external_id":"NCT07121127","title":"Effect of Fu's Subcutaneous Needling for Age-related Macular Degeneration","brief_summary":"This pilot randomized controlled trial aims to evaluate the efficacy and safety of FSN in improving symptoms in patients with dAMD.38 eligible participants will be recruited and randomly assign them in a 1:1 ratio to the FSN group and the control group. Throughout the study, both groups will take oral vitamin C and vitamin E supplements for a total of 28 days. Participants in the FSN group will receive four treatment sessions over two weeks. Both groups will be assessed at the end of the FSN treating period during the mid-study period, with ocular blood flow dynamics measured using OCTA, followed by a two-week follow-up. The primary outcome of this trial is the change in visual acuity from baseline to week 2, with secondary outcomes including visual field, visual function scale, macular thickness, central avascular zone area vascular density, and choroidal thickness.","overall_status":"Not Yet Recruiting","phases":["EARLY_PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"Zhiming Yan","enrollment":38,"countries":[],"start_date":"2026-07-07","completion_date":"2030-03-09","last_update_date":"2025-08-13","source_url":"https://clinicaltrials.gov/study/NCT07121127","editorial_summary":"A registered EARLY_PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 85 Years","comparator":null,"organization":"Guangdong Provincial Hospital of Traditional Chinese Medicine","interventions":["FSN+Vitamin supplement","Vitamin Supplements"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Best Corrected Visual Acuity — Day 14","Best Corrected Visual Acuity — FSN group:Baseline 2 days in FSN treatment period(days 4 and 11),follow-up day (day 28);…","Visual Function Questionnaire 25 — both groups:baseline, end of FSN treatment week (day 14) follow-up day (day 28)","OCTA metrics — baseline ,end of the FSN treatment week (day 14)","Visual field — both groups:baseline, end of FSN treatment week (day 14) follow-up day (day 28)"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Age - Related Macular Degeneration (AMD)","FSN+Vitamin supplement","Vitamin Supplements"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07121127","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-07-07 to 2030-03-09","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 85 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.863Z","intervention":["FSN+Vitamin supplement","Vitamin Supplements"],"participants":38,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"EARLY_PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Best Corrected Visual Acuity — Day 14","Best Corrected Visual Acuity — FSN group:Baseline 2 days in FSN treatment period(days 4 and 11),follow-up day (day 28);…","Visual Function Questionnaire 25 — both groups:baseline, end of FSN treatment week (day 14) follow-up day (day 28)","OCTA metrics — baseline ,end of the FSN treatment week (day 14)","Visual field — both groups:baseline, end of FSN treatment week (day 14) follow-up day (day 28)"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41739","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}